CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

CVS Caremark estimates between 25 to 30 million people use its ... Though the two drugs are both approved for weight loss, a study published in May funded by Eli Lilly found that patients on Zepbound ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

A lawsuit filed in federal court on behalf of the University of Pennsylvania and its health system alleges that 20 years of skyrocketing prices on drugs that treat diabetes, like insulin, can be ...

CVS Health Corp. will administer Eli Lilly and Co.’s COVID-19 treatment in patients’ homes and in long-term care facilities ... chief medical officer of CVS pharmacy-benefits manager Caremark.

Derica Rice, a longtime Eli Lilly chief financial officer, is set to take over at CVS Caremark on March 30, according to an internal CVS memo reviewed by The Wall Street Journal. Mr.

In the SGLT2 class of meds to treat diabetes, CVS removed Eli Lilly and Boehringer Ingelheim’s Jardiance and added Johnson & Johnson’s Invokana as a preferred option.

CVS Health selected former Eli Lilly CFO Derica Rice to serve as the president of its pharmacy benefit management division, CVS Caremark, according to The Wall Street Journal. Effective March 30 ...

Eli Lilly told the firm it is not interested in exclusive "one-of-one" deals with PBMs, while Novo Nordisk said CVS approached the drugmaker about the Wegovy agreement, according to Seigerman.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant. Skip to content. Main Navigation.